Siren Biotechnology blends two revolutionary therapeutic technologies into one for a novel approach to treating cancer.AAV gene therapy and cytokine immunotherapy are two revolutionary treatment approaches that Siren Biotechnology has combined into a single, redesigned modality. This approach overcomes significant obstacles and entirely transforms how tumor cells are eliminated and anti-tumor immunity is stimulated.
Trial Library is an oncology clinical trials company.
LatchBio develops a data infrastructure intended to build and disseminate the open-source infrastructure of the biocomputing revolution. Founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman, the company creates open-source machine learning and cloud infrastructure for the next generation of therapeutic discovery, thereby enabling biotech companies to find therapies faster and save on engineering.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
Nomic is a bioengineering company working to make the human proteome as broadly and easily accessible as the human genome. They are building the nELISA, a next-generation ELISA platform for measuring proteins at scale and at high throughput. They offer scientists protein profiling solutions to empower them to decide the scope and scale of their experiments.
LatchBio develops a data infrastructure intended to build and disseminate the open-source infrastructure of the biocomputing revolution. Founded in 2021 by Alfredo Andere, Kyle Giffin, and Kenny Workman, the company creates open-source machine learning and cloud infrastructure for the next generation of therapeutic discovery, thereby enabling biotech companies to find therapies faster and save on engineering.
Tendo Technologies Limited, founded in 2018 and based in London, develops innovative software aimed at enhancing economic security for frontline employees, particularly in the healthcare sector. The company's platform allows users to maintain a portable record of their work, including skills and hours worked, facilitating better management of workforce training and retention. By focusing on the integration of healthcare experiences, Tendo aims to improve clinical outcomes and operational efficiency for patients, clinicians, and caregivers alike. Their cloud-native and configurable solution streamlines workflows, enabling healthcare professionals to dedicate more time to patient care and less to administrative tasks. Through these efforts, Tendo aspires to create a more connected, efficient, and user-friendly healthcare environment.
Vesta Healthcare is an industry-leading technology and clinical services organization, dedicated to connecting caregiver insights to the rest of the care team. Vesta Healthcare proactively identifies the need for additional resources in the home and provides 24/7 telehealth support for caregivers and care recipients, with a focus on high-need, frail senior populations. Vesta partners with home care agencies, health plans and providers to create value-based population health programs that emphasize clinical quality, improved health outcomes and personalized engagement. Vesta Healthcare is headquartered in New York, NY.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases. Plexium's platform focuses on the discovery of next-generation TPD drugs that extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unraveling the boundless possibilities of true drug-like protein degraders. From molecular glues to monovalent degraders, the possibilities are endless across a wide variety of therapeutic areas.
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics.
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We are a biotechnology company scaling more like a technology company.
Auransa is a clinical stage drug development company who aims to invent high value, novel drugs for hard-to-treat diseases like cancer, auto-immune and neurological disorders using its proprietary AI platform and drug discovery expertise. The company's platform is used to understand biology of diseases at subtype level resolution, enabling it to predict compounds and targets of novel pharmacology for responder patient population. Current internal drug pipeline includes a first-in-class investigational new drug for cancer in clinical trials. Auransa has partnership with companies and institutions in the biopharma industry.
Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.
Braid Health is a digital health innovation company that develops an AI-powered diagnostic collaboration platform that improves the speed, quality, and workflow of radiologists and healthcare providers. Braid Health empowers radiologists and healthcare providers to deliver diagnoses for any patient, anywhere.
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes develops a platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that enables patients to participate in treatment research online and benefit from their own medical data.
LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine. Its protein engineering platform integrates several bleeding-edge technologies from the fields of machine learning, synthetic biology, and robotics.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics. The company's focus is to identify individuals and populations around the world who are extreme outliers for traits of medical relevance and to use innovative sequencing and analytic approaches to identify genes and pathways linked to these traits. Variant Bio was founded in 2018 and headquartered in Seattle, Washington.
Cala Health is a bioelectronic medicine company focused on developing wearable neuromodulation therapies for chronic diseases. The company integrates neuroscience and technology to provide individualized peripheral nerve stimulation. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor. Cala Health is also working on therapies for Parkinson's disease and other neurological conditions and areas in psychiatry, cardiology, and autoimmune disorders.
AllStripes is a healthcare technology company dedicated to unlocking new treatments for people with rare diseases. AllStripes develops a platform that generates regulatory-ready evidence to accelerate rare disease research and drug development, as well as a patient application that enables patients to participate in treatment research online and benefit from their own medical data.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Rivet is fixing the adversarial relationship between healthcare providers and payers, arming providers with more sophistication and productivity to improve financial transparency and operational efficiency.
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We are a biotechnology company scaling more like a technology company.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate our programs. We are a biotechnology company scaling more like a technology company.
3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.
Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.
Kyruus delivers proven provider search and scheduling solutions that help hospitals and health systems match patients with the providers best suited to care for them. The ProviderMatch suite of solutions—for consumers, access centers, and referral networks—enables a consistent patient experience across multiple points of access, while aligning provider supply with patient demand. The company’s proprietary provider data management platform forms the foundation of its solutions, powering them with accurate data by coupling data processing with administrative applications. Kyruus was founded in 2010 and is headquartered in Boston, Massachusetts.
3Scan is turning tissue into bits by building robotic microscopy tools and software for large-scale sample analysis and 3D visualizations. Many diseases emerge only at a tissue level, such as cancer, heart disease, lung disease, stroke, Alzheimer's, and diabetes. 3Scan enables higher throughput, greater quantification, and broader image analysis than what is currently possible with traditional histopathology. 3Scan's data-driven approach is expanding our understanding of tissue biology and will lead to the discovery of new diagnostics and therapeutics. The company was founded in 2011 and is headquartered in San Francisco, California.
Vium is a biotechnology company that develops digital biomarkers to transform preclinical research and animal welfare. It is fully accredited by AAALAC International and received an unprecedented AAALAC commendation for upholding the 3 Rs, the gold-standard framework for humane animal research. Customers run the spectrum of biotechnology, pharmaceutical, and computational drug discovery companies to academia and novel therapeutic labs. Vium's digital platform provides physiological biomarkers that enable better decisions on which compounds should be advanced to the clinic. The company's platform Digital Vivariumand Vium Cloud is the gold-standard in vivo platform combining computer vision, artificial intelligence, machine learning, and sensor technology to non-invasively collect and derive insights from digital biomarkers. The platform continuously captures physiological metrics and behaviors non-invasively, providing more sensitive and accurate data collection, leading to more replicable studies. Vium was founded in 2013 and is headquartered in San Mateo, California, United States.
Cala Health is a bioelectronic medicine company focused on developing wearable neuromodulation therapies for chronic diseases. The company integrates neuroscience and technology to provide individualized peripheral nerve stimulation. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor. Cala Health is also working on therapies for Parkinson's disease and other neurological conditions and areas in psychiatry, cardiology, and autoimmune disorders.
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
Auris Health, Inc. is a company based in Redwood City, California, focused on developing advanced robotics technology for medical applications. Founded in 2007, it specializes in creating innovative solutions for diagnostic and therapeutic bronchoscopic procedures. The company's flagship product, the Monarch Platform, utilizes small cameras and instruments to facilitate endoscopic procedures through natural body openings. This platform incorporates cutting-edge advancements in imaging technology, robotics, endoscope design, sensing, and data science, aiming to enhance patient outcomes and reduce medical costs. Additionally, Auris Health is developing a dual-arm microsurgical system designed for ophthalmic surgery, further expanding its capabilities in the medical robotics field. As a subsidiary of Johnson & Johnson, Auris Health continues to transform medical intervention through its integration of various technological innovations.
Private Equity Round in 2012
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Tempo Pharmaceuticals is a biotechnology company based in Madrid, Spain.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Kereos, Inc., a biotechnology company, develops targeted molecular imaging agents and therapeutics to detect and treat cancer and cardiovascular disease. The company offers KI-0001, a magnetic resonance imaging (MRI) agent for tumor detection that finds tumors and highlights growing regions in the tumor margin; and KI-100X, a targeted chemotherapeutics for solid tumors, which reduces angiogenesis in tumor and atherosclerosis models, as well as inhibits tumor growth. It also provides KI-0002, an MRI agent for cardiovascular disease detection via an undisclosed biomarker; KI-1004, an anti-restenotic that inhibits restenosis while preserving re-endotheliazation in angioplasty models; and KM-4419, a targeted chemotherapeutic for solid tumors that synergizes with several chemotherapeutics in blocking tumor growth and increasing survival. In addition, the company works with pharmaceutical and imaging companies for the development and commercialization of cardiovascular disease MRI agents, as well as development of molecular imaging systems. Kereos, Inc. was founded in 1999 and is based in St. Louis, Missouri.